Both inhibitors are currently under phase II clinical trials: factor B inhibitor in IgA nephropathy and PNH, factor D inhibitor in C3G nephropathy and PNH. The gene discussed is LIF; the disease is paroxysmal nocturnal hemoglobinuria.